ProPhase Labs Interest Expense 2011-2025 | PRPH

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense ProPhase Labs

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
764 K	1.15 M	295 K	-	167 K	54 K	213 K	18 K	10 K	13 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.15 M	10 K	298 K

Quarterly Interest Expense ProPhase Labs

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-45 K	-	-	30 K	-18 K	-	-33 K	8 K	215 K	-	201 K	201 K	233 K	-	296 K	323 K	251 K	-	41 K	-	-	-	-	-	-	-	15 K	4 K	96 K	-	125 K	151 K	54 K	-	53 K	53 K	52 K	-	1 K	1 K	1 K	-	1 K	1 K	2 K	-	3 K	2 K	3 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
323 K	-45 K	74.9 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Canopy Growth Corporation CGC	74.6 M	$ 1.68	-3.44 %	$ 181 M	Canada
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Assertio Holdings ASRT	2.78 M	$ 0.74	-3.53 %	$ 52.6 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Organogenesis Holdings ORGO	20 K	$ 4.76	-1.14 %	$ 627 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Pacira BioSciences PCRX	-373 K	$ 26.64	1.33 %	$ 1.23 B	USA
Emergent BioSolutions EBS	87.9 M	$ 12.27	7.44 %	$ 628 M	USA
Evoke Pharma EVOK	500 K	$ 10.97	0.14 %	$ 36.7 M	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Rockwell Medical RMTI	2.3 M	$ 0.88	-5.2 %	$ 20.5 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	$ 21.43	0.3 %	$ 2.04 B	France
Sonoma Pharmaceuticals SNOA	-10 K	$ 3.52	-2.07 %	$ 4.37 M	USA
Evolus EOLS	127 K	$ 7.14	1.42 %	$ 443 M	USA
Harrow Health HROW	21.3 M	$ 46.39	-1.43 %	$ 1.51 B	USA
China Pharma Holdings CPHI	27.4 K	$ 1.53	-1.92 %	$ 26.7 M	China
Bausch Health Companies BHC	-28 M	$ 6.87	-0.79 %	$ 2.51 B	Canada
Veru VERU	862 K	$ 2.39	-1.24 %	$ 322 M	USA
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
cbdMD YCBD	-29.5 K	$ 1.18	-3.28 %	$ 5.09 M	USA
Cumberland Pharmaceuticals CPIX	606 K	$ 3.04	20.16 %	$ 42.7 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Solid Biosciences SLDB	652 K	$ 5.77	-1.79 %	$ 236 M	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 4.34	6.9 %	$ 131 M	USA
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
Perrigo Company plc PRGO	900 K	$ 12.77	-2.85 %	$ 1.75 B	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
Sundial Growers SNDL	81 K	$ 1.96	-11.31 %	$ 3.37 M	Canada
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	3.13 M	$ 0.64	-0.91 %	$ 30.6 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
Tilray TLRY	46.6 M	$ 11.19	-7.9 %	$ 6.92 B	Canada
TherapeuticsMD TXMD	300 K	$ 1.7	-2.86 %	$ 17.7 M	USA
Zomedica Corp. ZOM	175 K	-	-0.21 %	$ 98 M	USA
Viatris VTRS	592 M	$ 11.65	-	$ 14.1 B	USA